61 /100
HIGH RISK
Score updated May 30, 2026

NXGL — NEXGEL, Inc. Dilution Risk Tracker

Track NXGL dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track NXGL — Get alerts when the score changes →

📊 Score Breakdown

📋 Offering Ability
40
💰 Cash Runway
85
📊 Float Risk
40
⚠️ Warrant Exposure
15
🔄Convertible Debt

🌦️ Dilution Forecast

⛈️
Warning
High probability of dilution event
58%
🔄 Reverse Split 70%
• 50-day avg $0.62 below $1 exchange minimum
• Only 4 months cash — financial pressure
📉 Score Deterioration 50%
• Score rose 39 points recently (worsening)
• Score in HIGH risk zone (61/100)
🔁 Convertible Conversion 40%
• Significant convertible debt: 24% potential dilution
• Elevated convertible risk (60/100)
🔔 Track NXGL — Get forecast alerts →

💹 Market Data

Market Cap$5.48M
Shares Outstanding9.13M
Float6.51M
Cash$317.0K
Debt$3.09M
Short InterestN/A

🏛 Institutional Holdings

13.4% institutional ownership
Source: Yahoo Finance · Detailed 13F holder data available for tracked tickers
🔔 Track NXGL for full holder detail →

📉 Short Interest

Short Interest195.7K
Days to Cover1.7
% of Float3.0%
FINRA data as of May 15, 2026

📁 Recent SEC Activity

xbrl XBRL CONVERTIBLE Mar 31, 2026
xbrl XBRL WARRANT Dec 31, 2025
8-K 8K EVENT Apr 21, 2026
8-K 8K EVENT Mar 10, 2026
8-K 8K EVENT Feb 11, 2026
Full SEC filing analysis available with free account

📰 Recent News

No recent news
Track NXGL Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking NXGL — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required
🔬 More Research for NXGL
📊 NXGL FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 NXGL Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.